Neurocrine is doubling down on epilepsy, striking its second agreement in as many months with a new deal that grants it the option to license an investigational treatment for a rare form of the disease.
The San Diego-based drug developer last month struck a deal with Xenon Pharmaceuticals (NASDAQ: XENE) that added an experimental treatment for a rare, hereditary form of early-onset epilepsy to its pipeline.
Now the San Diego-based drug developer has struck a partnership with Swiss biotech Idorsia. The companies Friday announced an agreement that gives Neurocrine the option to license Idorsia’s ACT-709478, a type of drug known… Read more »
UNDERWRITERS AND PARTNERS
